炎症を処理し、そしてグルココルチコイド作用を強化するためへのコルチコトロフ由来の糖タンパク質ホルモンの使用

Japanese Patent JP2005529171

A

The use of corticotroph-derived glycoprotein hormone (CGH) to potentiate glucocorticoid action and to reduce glucocorticoid-induced adrenocortical suppression is described. CGH can be co-administered with glucocorticoids to enable a lower dosage of glucocorticoids to be used and to prevent or reduce glucocorticoid-induced side-effects. The invention additionally provides methods for the use of CGH as a replacement for glucocorticoids, or for treatment of a broad range of inflammatory states. Further provided are methods for purification of recombinant CGH.

Kelly, James Dee.
Webster, Philippa Jay.
Dillon, Stacy Earl.
Organ, Shannon El.
Wolf, Anitla

JP2004511827A

September 29, 2005

June 10, 2003

Click for automatic bibliography generation  

Zymogenetics, Incorporated

A61K38/35; A61P1/04; A61P1/16; A61P3/04; A61P5/44; A61P5/46; A61P7/00; A61P7/04; A61P7/06; A61P9/00; A61P9/10; A61P11/00; A61P11/02; A61P11/06; A61P13/12; A61P17/00; A61P17/04; A61P17/06; A61P19/00; A61P19/02; A61P19/10; A61P25/00; A61P25/04; A61P25/18; A61P25/30; A61P29/00; A61P31/04; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P39/00; A61P41/00; A61P43/00; C07K1/16; C07K14/575; C07K14/59; C07K14/72; C07K19/00; C12N5/10; C12N15/09; G01N30/46; G01N30/88; G01N33/76; A61K38/00; (IPC1-7): A61K38/35; A61P1/04; A61P1/16; A61P3/04; A61P5/44; A61P5/46; A61P7/00; A61P7/04; A61P7/06; A61P9/00; A61P9/10; A61P11/00; A61P11/02; A61P11/06; A61P13/12; A61P17/00; A61P17/04; A61P17/06; A61P19/00; A61P19/02; A61P19/10; A61P25/00; A61P25/04; A61P25/18; A61P25/30; A61P29/00; A61P31/04; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P39/00; A61P41/00; A61P43/00; C07K1/16; C07K14/575; C07K14/72; C07K19/00; G01N30/46; G01N30/88

Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Kazuhiro Nakamura
Masaya Nishiyama

Previous Patent: Ｔ細胞エピトープをマッピングおよび除去する方法

Next Patent: エレクトロルミネセンス素子